Armistice Capital’s Ernexa Therapeutics Warrants ERNAW Stock Holding History

Armistice Capital’s Portfolio ERNAW Stock Details ERNAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Sell	160,000 -3,840,000	-96%	-$364K	﹤0.01%	327
2026 Q1	$112K	Buy	+4,000,000	New	+$237K	﹤0.01%	243

Other funds holding ERNAW

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Armistice Capital's ERNAW Position: Q2 2026 in Review

Armistice Capital reduced its Ernexa Therapeutics Warrants (ERNAW) stake by 96% in Q2 2026, selling an estimated $364K and leaving 160,000 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Armistice Capital first reported a position in ERNAW in Q1 2026 and has held it in 2 quarters since. The position peaked at $112K in Q1 2026. 6 funds tracked by Wall St. Rank hold ERNAW as of Q2 2026.

Armistice Capital held 160,000 shares of Ernexa Therapeutics Warrants worth $11.4K as of Q2 2026.
Armistice Capital sold 3,840,000 Ernexa Therapeutics Warrants shares in Q2 2026, an estimated $364K.
Ernexa Therapeutics Warrants made up ﹤0.01% of Armistice Capital's portfolio in Q2 2026, its #327 holding.
Armistice Capital first reported a position in Ernexa Therapeutics Warrants in Q1 2026 and has held it in 2 quarters since.
Armistice Capital's Ernexa Therapeutics Warrants position peaked at $112K in Q1 2026.
6 funds tracked by Wall St. Rank held Ernexa Therapeutics Warrants as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.